Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L, Settanni CR, Varca S, Laterza L, Lopetuso LR, Napolitano D, Schiavoni E, Turchini L, Fanali C, Alfieri N, Pizzoferrato M, Papa A, Pafundi PC, Armuzzi A, Gasbarrini A, Pugliese D, Scaldaferri F.
Parisio L, et al. Among authors: varca s.
J Gastrointestin Liver Dis. 2023 Dec 22;32(4):452-459. doi: 10.15403/jgld-5084.
J Gastrointestin Liver Dis. 2023.
PMID: 38147610
Free article.